Supplementary Figure 1. miRNA-21 is upregulated in HNSCC tumors.

Supplementary Figure 2. RT-qPCR validation of miRNA-21 overexpression by transient transfection. (A) pre-miRNA-21 and (B) miRNA-21 expression level.

Supplementary Figure 3. miRNA-21 overexpression stimulates cell proliferation. All measurements were obtained with the Cell Counting Kit -8 cell proliferation assay. *p<0.01.

Supplementary Figure 4. miRNA-21 loses specificity for CLU transcript when miRNA-21 binding seed sequence is deleted from the CLU 3’UTR sequence. *p<0.03.

Supplementary Figure 5. Relative expression of CLU-1 in normal and HNSCC cell lines.

Supplementary Figure 6. RT-qPCR validation of CLU-1 overexpression by transient transfection.

Supplementary Figure 7. CLU-1 has growth inhibitory effects in JHU-O28, FaDu and SCC9 HNSCC cell lines. Overexpression of CLU-1 inhibits cell proliferation. All measurements were obtained by taking direct cell counts at each time point. *p<0.05.

Supplementary Table 1. Clinical characteristics of discovery cohort.

Supplementary Table 2. Clinical characteristics of mRNA expression array cohort.

Supplementary Table 3. Clinical characteristics of validation cohort.

Supplementary Table 4. miRNA array analysis of discovery cohort.

Supplementary Table 5. miRNA array significant call signals.

Supplementary Table 6. RT-qPCR validation of miRNA array.

Supplementary Table 7. has-mir-21 gene target prediction (miRanda).

Supplementary Table 8. has-mir-21 gene target prediction (TargetScan 4.2).

Supplementary Table 9. has-mir-21 gene target prediction (PicTar).
Supplementary Table 10. mRNA expression changes after transient transfection of miR-21 in NOKSI.

Supplementary Table 11. Differentially expressed mRNAs in HNSCC tumors.